期刊
PEPTIDES
卷 73, 期 -, 页码 95-100出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2015.09.006
关键词
Oxyntomodulin; Glucagon; GLP-1; cAMP
资金
- MRC
- BBSRC
- NIHR [FP7- HEALTH- 2009-241592]
- NIHR Imperial Biomedical Research Centre Funding Scheme
- BBSRC [BB/E52708X/1] Funding Source: UKRI
- MRC [MR/L013088/1, G0802390] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: researchfish
- Medical Research Council [G0802390, MR/L013088/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0507-10337, NF-SI-0513-10080] Funding Source: researchfish
Oxyntomodulin analogues offer a novel treatment for obesity. However during analogue screening in a rat model increased food intake was consistently observed. To further investigate this finding, a series of representative analogues (OXM14 and OXM15) and their Glu-3 equivalents (OXM14E3 and OXM15E3) were administered to rats for 7 days and food intake and bodyweight measurements taken. To investigate the role of glucagon receptor activation glutamate (Glu/E) was substituted at amino acid position 3. GLP1 and glucagon receptor efficacy of the oxyntomodulin analogues and their Glu-3 counterparts were measured at the rat receptors in vitro. Doses of 25 n mol/kg of OXM14 and OXM15 increased food intake by up to 20%. Bodyweight was not significantly increased. Food intake was not increased with the Glu-3 peptides, indicating that a glucagon receptor mechanism may be responsible for the increase in food intake. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据